Top Markets
Coin of the day
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Rang in Aktien #16324
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Aktienkurs
$0.94180721
Marktkapitalisierung
$22.26M
Veränderung (1 Tag)
0.38%
Veränderung (1 Jahr)
-14.35%
Land
FR
Handel Valbiotis SA (ALVAL)

Kategorie

Dividendenrendite-Verlauf für Valbiotis SA (ALVAL)
Dividendenrendite (TTM) von Valbiotis SA (Aktienkürzel: ALVAL) zum 2023-12-31: 0.00%
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Valbiotis SA (ALVAL) von 2015 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber